The biotech sector is being tested — and rebuilt. The  2026 Yale Innovation Summit Biotech Track, taking place May 27-28 on Yale's campus, gathers the founders, investors, and researchers who are doing the rebuilding. Designed for founders, investors, researchers, and advocates, the track covers the themes defining biotech's next chapter: capital strategy, women's health, patient-driven R&D, gene therapy, and accelerating the road from discovery to therapy. 

The theme, emerging across the track, is both pragmatic and optimistic. While recent years have tested early-stage companies, the underlying engine of discovery has not slowed. Instead, it is being reshaped by new funding models, sharper patient engagement, and a renewed focus on rapidly translating breakthrough science into real therapies. 

The program kicks off with our annual Trends in Life Science Investing, examining how capital is moving, where it is hesitating, and what signals investors are watching most closely. These conversations anchor the track in market realities and identify  areas of greatest opportunity. 

From there, the spotlight turns to one of the most consequential and underdeveloped frontiers in the field. The Summit will introduce a new focus on Women’s Health Innovation, paired with a dedicated pitch session designed to elevate founders addressing historically overlooked conditions and markets. This addition reflects a broader shift in biotech acknowledging that 52% of the population should no longer be considered a niche market but rather one with great  commercial potential. 

Across indications, a central theme emerges: the growing influence of patients in shaping the research pipeline. Sessions on Patient Advocacy and Early-Stage R&D explore how lived experience is funding early-stage drug development, influencing policies that impact research funding, and redefining success in therapeutic development. These discussions underscore a shift away from purely top-down models of innovation toward participatory, patient and caregiver-driven approaches.

At the same time, the biotech track confronts one of the field’s most persistent challenges: how to fund early discovery. Attendees will get to meet funders who are active in early stage investing and offer nondilutive capital.  Through their reverse pitches, attendees will hear directly what these funds and companies are looking for and how to approach them.

Few areas capture the current tension in biotech more clearly than cell and gene therapy. The panel titled "Is this the end of Cell and Gene Therapy or…?" leans into skepticism while reframing the conversation. This session will evaluate and debate the challenges facing the current generation of therapies with the most recent $7B cell therapy biotech acquisition highlighting it is indeed, not the end.  As the market recalibrates expectations around scalability, cost, and clinical impact, scientific progress continues to challenge these hurdles and find new ways forward.

This forward-looking perspective carries through to discussions on Translating Science to Therapies, where founders, investors, and researchers will examine the innovations in research tools at move ideas from lab benches to patients. Particular attention will be paid to advances in platform technologies that drive more efficient and translatable pre-clinical development strategies. The emphasis is not only on breakthrough discovery, but on execution. How do promising technologies survive the long arc of development? What innovation is required to bring them to patients faster and more effectively?

Throughout the track, these questions are anchored by voices from across the ecosystem. Founders share the realities of building in uncertain conditions. Investors reflect on how their strategies are evolving. Innovators offer a view into the next generation of scientific advances.  

As Morag Grassie, Executive Director of the Blavatnik Fund for Innovation at Yale Ventures, said:

“There is a tendency to read the preclinical investment environment as challenging. What we are seeing instead are start-ups boot strapping, addressing the most important derisking questions and offering investors great opportunities. The early pipeline is active, ambitious, and full of possibility. The challenge now is how we support it with the right capital, the right partnerships, and the right sense of urgency.” 
 

Beyond the panels, the Biotech Track creates space for connection. Community-driven moments such as the amplifyHERscience networking session bring together scientists, founders, and investors in conversations that extend beyond the stage. The track also highlights innovation in action, with the Biotech Showcase featuring emerging companies and the Blavatnik Accelerator Award pitches spotlighting breakthrough research on day one. Together, these gatherings reflect the Summit’s broader goal: not just to showcase innovation, but to build the relationships that sustain it.

The result is a program that meets the moment with clarity and momentum. It acknowledges the pressures facing biotech today while making a compelling case for its future. Attendees  will leave with a sharper sense of direction, new connections and opportunities and a renewed confidence in what this field can deliver.